What are Dihexa's side effects?
Unknown in humans — no one has published a human study. The concern researchers raise is mechanistic: c-Met activation and cancer biology.
No human trial data
Dihexa Side Effects
No human data at all — rodent studies only; a mechanism with a specific oncology concern
Dihexa has never been given to a human in a published study. Everything known comes from rodent work on cognition. The mechanistic caution is specific and serious: Dihexa acts on the HGF/c-Met pathway, and c-Met signalling is a well-established driver in several cancers. The previous version of this page listed side effects with frequencies; none of that was real.
Research-use information only. Research-grade Dihexa is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
What is reported
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Rodent studies | not quantified | Cognitive effects reported; no formal toxicology published. | Benoist et al. 2011; McCoy et al. 2013 |
What is not known
- •Every human parameter — tolerability, pharmacokinetics, dose.
- •Long-term consequences of c-Met activation.
Mechanism-based cautions
- •HGF/c-Met is an oncogenic signalling axis; a potent agonist carries a theoretical tumour-promotion risk that no study has examined.
- •Very high potency and lipophilicity — dosing errors are consequential.
Regulatory status: Not approved anywhere; no clinical development.
References
- McCoy AT, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics, 2013.